US2017056480A1PendingUtilityA1

Erythropoietin and fibronectin compositions for therapeutic and cosmetic applications

52
Assignee: REMEDOR BIOMED LTDPriority: Aug 16, 2007Filed: Nov 14, 2016Published: Mar 2, 2017
Est. expiryAug 16, 2027(~1 yrs left)· nominal 20-yr term from priority
Inventors:Saher Hamed
A61P 43/00A61P 7/04A61P 9/10A61P 39/04A61P 31/00A61P 3/02A61P 17/02A61K 38/39A61K 38/1816A61K 38/22A61K 9/0014A61K 31/70A61K 9/06A61K 47/32A61K 31/21A61K 38/19A61K 31/198A61K 38/36A61K 38/43
52
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A method of promoting wound healing or connective tissue reconstruction and a method of treating ischemia in a subject in need thereof are disclosed. The methods comprising topically administering to the subject about 10-30 mg per cm 2 wound tissue of Erythropoietin and about 100-300 mg per cm 2 wound tissue of Fibronectin, thereby promoting wound healing or connective tissue reconstruction or treating ischemia in the subject. Unit dosage forms, pharmaceutical compositions, cosmetic compositions and formulations comprising Erythropoietin and/or Fibronectin are also disclosed.

Claims

exact text as granted — not AI-modified
1 - 18 . (canceled) 
     
     
         19 . A method of treating ischemia in a subject in need thereof, the method comprising topically administering to the subject about 10-30 μg per cm 2  tissue of Erythropoietin and about 100-300 μg per cm 2  tissue of Fibronectin, thereby treating ischemia in the subject. 
     
     
         20 . The method of  claim 19 , wherein a dose of said Erythropoietin is about 20 μg per cm 2  tissue. 
     
     
         21 . The method of  claim 19 , wherein a dose of said Fibronectin is about 200 μg per cm 2  tissue. 
     
     
         22 . The method of  claim 19 , wherein said administering of said Erythropoietin and said Fibronectin is effected concomitantly. 
     
     
         23 . The method of  claim 19 , wherein said Erythropoietin and said Fibronectin are in a co-formulation. 
     
     
         24 . The method of  claim 19 , wherein said Erythropoietin and said Fibronectin are in separate formulations. 
     
     
         25 . The method of  claim 20 , wherein a dose of said Erythropoietin is about 20 μg per cm 2  tissue. 
     
     
         26 . The method of  claim 19 , wherein wound healing is promoted in the subject. 
     
     
         27 . The method of  claim 19 , wherein connective tissue reconstruction is promoted in the subject. 
     
     
         28 . A method of promoting wound healing or connective tissue reconstruction in a subject in need thereof, the method comprising topically administering to the subject about 10-30 μg per cm 2  tissue of Erythropoietin and about 100-300 μg per cm 2  tissue of Fibronectin, thereby promoting wound healing or connective tissue reconstruction in the subject.

Join the waitlist — get patent alerts

Track US2017056480A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.